Tag: non-transplant eligible MCL treatment

Home / non-transplant eligible MCL treatment

Categories

Acalabrutinib with bendamustine and rituximab is approved by the USFDA for previously untreated mantle cell lymphoma

On January 16, 2025, the Food and Drug Administration granted conventional approval to acalabrutinib (Calquence, AstraZeneca) in combination with bendamustine and rituximab for adults with previously ...
non-transplant-eligible-mcl-treatment

Scan the code